View in EDS PDF Full Text

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.

Saved in:
Bibliographic Details
Title: Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Authors: Ramanathan RK; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. ramanathanrk@upmc.edu, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2006 Apr; Vol. 57 (4), pp. 465-74. Date of Electronic Publication: 2005 Aug 25.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0344-5704 (Print) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 16133531
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ramanathan+RK%22">Ramanathan RK</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. ramanathanrk@upmc.edu<br /><searchLink fieldCode="AU" term="%22Fakih+M%22">Fakih M</searchLink><br /><searchLink fieldCode="AU" term="%22Mani+S%22">Mani S</searchLink><br /><searchLink fieldCode="AU" term="%22Deutsch+M%22">Deutsch M</searchLink><br /><searchLink fieldCode="AU" term="%22Perez+RP%22">Perez RP</searchLink><br /><searchLink fieldCode="AU" term="%22Ritter+MA%22">Ritter MA</searchLink><br /><searchLink fieldCode="AU" term="%22Eiseman+JL%22">Eiseman JL</searchLink><br /><searchLink fieldCode="AU" term="%22Ivy+SP%22">Ivy SP</searchLink><br /><searchLink fieldCode="AU" term="%22Trump+DL%22">Trump DL</searchLink><br /><searchLink fieldCode="AU" term="%22Belani+CP%22">Belani CP</searchLink><br /><searchLink fieldCode="AU" term="%22Parise+RA%22">Parise RA</searchLink><br /><searchLink fieldCode="AU" term="%22Potter+DM%22">Potter DM</searchLink><br /><searchLink fieldCode="AU" term="%22Egorin+MJ%22">Egorin MJ</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2006 Apr; Vol. 57 (4), pp. 465-74. <i>Date of Electronic Publication: </i>2005 Aug 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>0344-5704 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=16133531
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00280-005-0071-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 465
    Titles:
      – TitleFull: Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ramanathan RK
      – PersonEntity:
          Name:
            NameFull: Fakih M
      – PersonEntity:
          Name:
            NameFull: Mani S
      – PersonEntity:
          Name:
            NameFull: Deutsch M
      – PersonEntity:
          Name:
            NameFull: Perez RP
      – PersonEntity:
          Name:
            NameFull: Ritter MA
      – PersonEntity:
          Name:
            NameFull: Eiseman JL
      – PersonEntity:
          Name:
            NameFull: Ivy SP
      – PersonEntity:
          Name:
            NameFull: Trump DL
      – PersonEntity:
          Name:
            NameFull: Belani CP
      – PersonEntity:
          Name:
            NameFull: Parise RA
      – PersonEntity:
          Name:
            NameFull: Potter DM
      – PersonEntity:
          Name:
            NameFull: Egorin MJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2006 Apr
              Type: published
              Y: 2006
          Identifiers:
            – Type: issn-print
              Value: 0344-5704
          Numbering:
            – Type: volume
              Value: 57
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cancer chemotherapy and pharmacology
              Type: main
ResultId 1